Appendix C
Workshop Attendee List

Patricia Adams

National Pharmaceutical Council


Deborah Ascheim

Columbia University


Carol Ashton

University of Alabama, Birmingham


David Atkins

Agency for Healthcare Research and Quality


Wade Aubry

Health Technology Center


Jerry Avorn

Harvard Medical School


Peter Bach

Memorial Sloan-Kettering Cancer Center


Mara Baer

Blue Cross Blue Shield Association


Bob Ball

Food and Drug Administration


Michael Banyas

U.S. Department of Health and Human Services


Dennis Barbour

Society for Investigative Dermatology


Bart Barefoot

GlaxoSmithKline


Barbara A. Bartman

Agency for Healthcare Research and Quality


Rachel Behrman

Food and Drug Administration



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 409
Appendix C Workshop Attendee List Patricia Adams Mara Baer National Pharmaceutical Council Blue Cross Blue Shield Association Deborah Ascheim Bob Ball Columbia University Food and Drug Administration Carol Ashton Michael Banyas University of Alabama, U.S. Department of Health and Birmingham Human Services David Atkins Dennis Barbour Agency for Healthcare Research Society for Investigative and Quality Dermatology Wade Aubry Bart Barefoot Health Technology Center GlaxoSmithKline Jerry Avorn Barbara A. Bartman Harvard Medical School Agency for Healthcare Research and Quality Peter Bach Memorial Sloan-Kettering Cancer Rachel Behrman Center Food and Drug Administration 09

OCR for page 409
0 REDESIGNING THE CLINICAL EFFECTIVENESS RESEARCH PARADIGM Rami Ben-Joseph David Burns sanofi-aventis National Institute of Allergy and Infectious Diseases Debra Berlanstein University of Maryland, Baltimore Dale Burwen Food and Drug Administration Elise Berliner Agency for Healthcare Research Robert Califf and Quality Duke University Medical Center Donald Berry James Carey The University of Texas M.D. Novartis Pharmaceuticals Anderson Cancer Center Corporation Richard Billingsley Kristin Carman George Washington University American Institutes for Research Medical Center Linda Carter Ashley Boam Johnson & Johnson Food and Drug Administration Stephanie Chang Douglas Boenning Agency for Healthcare Research U.S. Department of Health and and Quality Human Services Yen-pin Chiang Rosemary Botchway Agency for Healthcare Research Primary Care Coalition of and Quality Montgomery County Grace Chow Mary Jo Braid-Forbes National Institutes of Health The Moran Company Carolyn Clancy Amanda Brodt Agency for Healthcare Research AcademyHealth and Quality Lynda Bryant-Comstock Alex Clyde GlaxoSmithKline Medtronic, Inc. Jonca Bull Andrew Cohen Genentech AGC & Associates Perry D. Cohen Parkinson Pipeline Project

OCR for page 409
 APPENDIx C Denis Cortese Louis Diamond Mayo Clinic Thomson Healthcare Kenyatta Cosby Denise Dougherty Johns Hopkins Medical Institute Agency for Healthcare Research and Quality Catherine Craven Johns Hopkins University Clay Dunagan BJC HealthCare Thomas Croghan Mathematica Policy Research Philip Duvall Avalere Health William Crown i3 Innovus Jill Eden Institute of Medicine Frederick Curro New York University Maggie Elestwani Memorial Hermann-Texas J. Nico D. de Neeling Medical Center Health Council of the Netherlands Lynn Etheredge Vicky Debold George Washington University National Vaccine Information Center Frank Evans National Institutes of Health Donald DeNucci National Institutes of Health and Christina Farup Department of Veterans Affairs Novartis Nancy Derr Shamiram Feinglass Food and Drug Administration Centers for Medicare & Medicaid Services Kelly Devers Virginia Commonwealth Karen Wolk Feinstein University Jewish Healthcare Foundation Deirdre DeVine Harvey Fineberg Tufts-New England Medical Institute of Medicine Center Brian Firth Christopher Dezii Cordis Bristol-Myers Squibb Company Johnson & Johnson

OCR for page 409
2 REDESIGNING THE CLINICAL EFFECTIVENESS RESEARCH PARADIGM Leslye Fitterman Mark Grant Centers for Medicare & Medicaid Blue Cross Blue Shield Association Services Mary Grealy David Flum Healthcare Leadership Council University of Washington Lea Greenstein Steven Fox Institute of Medicine Agency for Healthcare Research and Quality Jerry Grossman Health Care Delivery Project Susan Friedman American Osteopathic Association Joao Guerra Hospital Reynaldo Santos Richard Fry Foundation for Managed Care Stuart Guterman Pharmacy The Commonwealth Fund Jean Paul Gagnon Kara Haas sanofi-aventis Ethicon Endo-Surgery Dan Galper J. Michael Hall American Psychological American Liver Foundation Association Andrea Harabin Annetine Gelijns National Heart, Lung, and Blood Columbia University Institute Sharon Gershon Nancy Hardt Food and Drug Administration Office of Speaker Nancy Pelosi Kim Gilchrist Alex Hathaway AstraZeneca GlaxoSmithKline Don Goffena Anthony Hayward WL Gore and Associates, Inc. National Institutes of Health Mark Gorman Erin Holve National Coalition for Cancer AcademyHealth Survivorship Peter Honig Tina Grande Merck & Co., Inc. Healthcare Leadership Council

OCR for page 409
 APPENDIx C Mary Horlick Ruth Kirby National Institutes of Health National Heart, Lung, and Blood Institute Jane Horvath Merck & Co., Inc. Isaac Kohane Harvard Medical School Lia Hotchkiss Agency for Healthcare Research Rachel Kramer and Quality The Moran Company Julianne Howell Alan Krensky Centers for Medicare & Medicaid National Institutes of Health Services Nora Kronenthal Kathy Hudson National Science Foundation Genetics and Public Policy Center Cara Krulewitch Belinda Ireland Food and Drug Administration BJC HealthCare Joel Kupersmith Gretchen Jacobson Department of Veterans Affairs Congressional Research Service Hanns Kuttner Laura Johnson Office of Senator Orrin Hatch National Institutes of Health Arnold Kuzmack Mary Joyce Food and Drug Administration National Heart, Lung, and Blood Institute William Lang American Association of Colleges Peter Juhn of Pharmacy Johnson & Johnson Jeanne Larsen Elisabeth Kato Georgetown University Medical Hayes, Inc. Center Bruce Kelly Eric Larson Mayo Clinic Group Health Cooperative Grace Kelly Michael Lauer National Institutes of Health Division of Prevention and Population Science

OCR for page 409
 REDESIGNING THE CLINICAL EFFECTIVENESS RESEARCH PARADIGM Cato Laurencin Ruth Lopert University of Virginia George Washington University Martha Lee Bryan Luce Food and Drug Administration United BioSource Corporation Teresa Lee Carole Magoffin AdvaMed National Minority Quality Forum Anna Legreid Dopp Michele Malloy Office of Senator Lieberman Georgetown University Medical Center Carole Lever MedStar—Union Memorial Teri Manolio Hospital National Human Genome Research Institute Allyson H. Lewis American Liver Foundation JoAnn Manson Harvard Medical School Kenneth Lin Agency for Healthcare Research Norman Marks and Quality Food and Drug Administration Susan Lin Ivonne Martinez National Center for Health Georgetown University Statistics Noel Mazade Tsai-Lien Lin National Association of State Center for Biologics Evaluation Mental Health Program and Research Directors Research Institute, Inc. Keith Lind AARP Mark McClellan Brookings Institution Anne Linton The George Washington University Kathleen McCormick Science Applications International Alicia Livinski Corporation National Institutes of Health Newell McElwee Kathleen Lohr Pfizer, Inc. RTI International

OCR for page 409
 APPENDIx C Scott McKenzie Sharon-Lise Normand Johnson & Johnson Harvard Medical School Kathryn McLaughlin Parivash Nourjah America’s Health Insurance Plans Agency of Healthcare Research and Quality Robert Mechanic Brandeis University Patrick O’Connor Food & Drug Administration Carolyn Miles National Institutes of Health Keith Ortiz VantagePoint Consulting Group Amy Miller Personalized Medicine Coalition Awo Osei-Anto Avalere Health Wilhelmine Miller George Washington University Dina Paltoo National Institutes of Health Kelly Montgomery American Diabetes Association Ronald Paulus Geisinger Health System Hazel Moran Mental Health America L. Gregory Pawlson National Committee for Quality Alan Moskowitz Assurance Columbia University Stephen Pelletier Esther Myers Pelletier Editorial The American Dietetic Association Eleanor M. Perfetto Perfetto Garry Neil Pfizer, Inc. Johnson & Johnson Gary Persinger David Nexon National Pharmaceutical Council AdvaMed Sarah Pitluck George Neyarapally Genentech Agency for Healthcare Research and Quality Rich Platt Harvard Medical School and John Niederhuber Harvard Pilgrim Health Care National Cancer Institute

OCR for page 409
 REDESIGNING THE CLINICAL EFFECTIVENESS RESEARCH PARADIGM Janet Prvu-Bettger John Rush University of Pennsylvania University of Texas Southwestern Medical Center Antonello Punturieri National Heart, Lung, and Blood Stephen Ryan Institute AstraZeneca G. Gregory Raab Susan Samson Raab & Associates, Inc. University of California San Francisco Gurvaneet Randhawa Agency for Healthcare Research Karen Sanders and Quality American Psychiatric Association Purva Rawal Lewis Sandy Office of Senator Lieberman United Healthcare Wayne Ray Phil Sarocco Vanderbilt University School of Boston Scientific Medicine Jyme Schafer John Rayburn Centers for Medicare & Medicaid Healthcare Leadership Council Services Carolina Reyes Donna Schaffer Genentech, Inc. Center for Medical Technology Policy John C. Ring American Heart Association Kristin Schneeman FasterCures Mark Roberts Center for Research on Health Sebastian Schneeweiss Care Harvard Medical School Yves Rosenberg Lawrence Schott National Heart, Lung, and Blood Centers for Medicare & Medicaid Institute Services Wayne Rosenkrans David Schulke AstraZeneca Pharmaceuticals American Health Quality Association

OCR for page 409
 APPENDIx C Sandy Schwartz Ansalan Stewart University of Pennsylvania Office of the Assistant Secretary for Policy and Planning Art Sedrakyan Agency for Healthcare Research Catherine Stoney and Quality National Institutes of Health Jodi Segal Michael Stoto Johns Hopkins University School Georgetown University of Medicine Paul Strasberg Joe Selby National Center for Education Kaiser Permanente Evaluation Steve Severance David Sugano Vivalog Schering-Plough Pharmaceuticals Gail Shearer Kara Suter Consumers Union The Moran Company George Silberman Betty Tai Cancer Policy Group, LLC Center of Clinical Trials Network Rebecca Singer Cohen Jorge Tavel United BioSource Corporation National Institute of Allergy and Infectious Diseases Jean Slutsky Agency for Healthcare Research Robert Temple and Quality Food and Drug Administration Scott Smith Anne Trontell Agency for Healthcare Research Agency for Healthcare Research and Quality and Quality Melissa Stegun Sean Tunis George Washington University Center for Medical Technology Policy Donald Steinwachs Johns Hopkins University Karen Ulisney National Institutes of Health Melissa Stevens FasterCures

OCR for page 409
 REDESIGNING THE CLINICAL EFFECTIVENESS RESEARCH PARADIGM Craig Umscheid Brian Waterman University of Pennsylvania Health BJC HealthCare System Kathleen Weis Douglas Varner Pfizer, Inc. Georgetown University Medical Center Sue West University of North Carolina Don Vena The EMMES Corporation Karen Williams National Pharmaceutical Council Corinne Vosmer Vosmer Science Applications International Todd Williamson Corporation sanofi-aventis Alec Walker Michael Wittek Harvard University Medtronic, Inc. Marc Walton Kim Wittenberg Food and Drug Administration Agency for Healthcare Research and Quality Cunlin Wang Food and Drug Administration Hui-Hsing Wong Office of the Assistant Secretary Philip Wang for Planning and Evaluation National Institute of Mental Health Nelda Wray University of Alabama, Gretchen Wartman Birmingham National Minority Quality Forum Laura Zick Eli Lilly and Company

OCR for page 409

OCR for page 409
OTHER PUBLICATIONS IN THE LEARNING HEALTHCARE SYSTEM SERIES The Learning Healthcare System Evidence-Based Medicine and the Changing Nature of Healthcare Leadership Commitments to Improve Value in Healthcare: Finding Common Ground Value in Health Care: Accounting for Cost, Quality, Safety, Outcomes, and Innovation Redesigning the Clinical Effectiveness Research Paradigm: Innovation and Practice-Based Approaches Clinical Data as the Basic Staple of Health Learning: Creating and Protecting a Public Good (forthcoming) Learning What Works: Infrastructure Required for Comparative Effectiveness Research (forthcoming) Engineering a Learning Healthcare System: A Look at the Future (forthcoming)